Pixuvri (pixantrone)

By introducing small molecules such as pixantrone dimaleate (PIX) as molecular fillers, the stability of the DNA nanomaterials and the detection sensitivity of the detection system were significantly improved...Analysis of 60 clinical samples demonstrated that the system could effectively distinguish non-metastatic and metastatic patients, achieving high specificity (91.9%) and sensitivity (95.7%), and the results were consistent with clinical diagnosis. This study provided an effective liquid biopsy strategy for monitoring lung cancer metastasis risk.

P2, N=74, Completed, The Lymphoma Academic Research Organisation | Active, not recruiting --> Completed

P=N/A, N=15, Active, not recruiting, IRCCS Azienda Ospedaliero-Universitaria di Bologna

These findings suggest that pixantrone may be a promising drug for ovarian cancer patients by targeting MCM2 in the clinic.

Pixantrone caused DNA damage and exhibited inhibitory effects on SCLC cells in vitro and in a patient-derived xenograft mouse model. These results indicated that SMARCAL1 functions as an oncogene in SCLC, and pixantrone as a SMARCAL1 inhibitor bears therapeutic potentials in this deadly disease.

HOIL-1 is critical in promoting sorafenib resistance and CSC properties of HCC through Notch1 signaling. Pixantrone targeting HOIL-1 restrains the sorafenib resistance and provides a potential therapeutic intervention for HCC.

P2, N=74, Active, not recruiting, The Lymphoma Academic Research Organisation | Recruiting --> Active, not recruiting

In this real-life experience, pixantrone demonstrated long-term efficacy in a cohort of R/R DLBCL cases who had previously received at least two prior regimens; many of whom had characteristics associated with poor prognosis.

"The research was funded by: Servier Laboratoires Introduction: The Nordic Lymphoma Group (NLG) performed a dose-finding/expansion trial evaluating pixantrone, etoposide, bendamustine and, in CD20+ lymphomas, rituximab (P[R]EBEN) in patients (pts) with relapsed diffuse large B-cell (DLBCL) or peripheral T-cell (PTCL) lymphomas. The P[R]EBEN regimen is feasible on an out-pt basis and shows encouraging response rates and DoR. In PTCL, we observed an overrepresentation of AML/MDS, possibly related to the use of etoposide in multiple treatment lines. Gene expression analysis identified signatures and single genes predictive of long-term response."

Pixantrone has insufficient activity in the second- and third-line MBC setting. It appears, however, to have limited cardiotoxicity. (ClinicalTrials.gov ID: NCT01086605).